Beovu (brolucizumab-dbll) / Novartis, Santen, China Medical System - LARVOL DELTA

Intravitreal Brolucizumab Use for Retinal Vascular Diseases in Resource-Constrained Settings: A Retrospective Study From Bangladesh. (PubMed, Cureus) - "Conclusion Brolucizumab demonstrated visual gain in the short term with a favorable safety profile in a series of cases in the real-world settings of Bangladesh. Larger studies with extended follow-up can further elucidate its long-term utility."

Journal • Retrospective data • Age-related Macular Degeneration • Cardiovascular • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders

Vitrectomy with Subretinal Tissue Plasminogen Activator for Submacular Hemorrhage: A Multicenter Retrospective Analysis of Functional and Anatomical Outcomes Across Multiple Etiologies. (PubMed, Clin Ophthalmol) - "Mean anti-VEGF use was 1.2 injections/eye (bevacizumab 88.2%, brolucizumab 11.8%). PPV with subretinal tPA achieved rapid hemorrhage clearance, significant visual gain, and durable anatomical restoration with minimal complications and limited anti-VEGF need. It offers an effective, safe option for large SMH across etiologies, enabling timely foveal recovery and improved long-term functional outcomes."

Journal • Retrospective data • Age-related Macular Degeneration • Cardiovascular • Cataract • Hematological Disorders • Macular Degeneration • Mood Disorders • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Medicare Trends in Intravitreal Anti-VEGF Use: A Population-Based Study (2014-2023). (PubMed, Ophthalmol Retina) - "Intravitreal anti-VEGF utilization among Medicare beneficiaries increased substantially from 2014 to 2023, driven primarily by growth in aflibercept use and rapid adoption of faricimab. Reimbursement for certain branded agents declined over time, while substantial geographic variation in injection rates persisted across states. Continued monitoring is warranted as biosimilars, emerging agents, and novel delivery systems enter the U.S. market."

Journal • Medicare • Reimbursement • US reimbursement • Cardiovascular • Ophthalmology

Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy. (PubMed, Clin Ophthalmol) - "The anti-VEGF agents including aflibercept 2 mg, aflibercept 8 mg, brolucizumab, faricimab, and ranibizumab-BS were assessed. Intravitreal injection using the aflibercept 2 mg prefilled syringe may deliver approximately 1.5 times the intended volume into the eye. This may raise safety concerns, such as the risk of transient vision loss due to marked immediate IOP elevation, and may also affect clinical outcomes and the validity of clinical trials."

Journal

Results from a French brolucizumab access program for pretreated patients with neovascular age-related macular degeneration. (PubMed, Eur J Ophthalmol) - "Intraocular inflammation rate was 8.0% (n = 29).ConclusionResults demonstrated functional and anatomical benefits of brolucizumab in patients with refractory or suboptimally controlled nAMD, with a manageable safety profile. These findings highlight the potential of brolucizumab to reduce treatment burden in chronic nAMD."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Intraocular inflammation after intravitreal injection of second-generation anti-VEGF agents observed in a tertiary center over 12 months: What are the specific features? (PubMed, J Fr Ophtalmol) - "Next-generation anti-VEGF agents carry a non-negligible risk of IOI, most often of moderate severity and with good outcomes after topical corticosteroids. Symptoms suggestive of IOI, as well as confirmed IOI, should contraindicate further injections with the same molecule. No current consensus exists to guide the choice of an alternative anti-VEGF agent after IOI, aside from the clear contraindication for brolucizumab."

Journal • Cardiovascular • Glaucoma • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis • Vasculitis

Prevalence of Polypoidal Choroidal Vasculopathy Beyond Recalcitrant Macular Neovasculopathies in a European AMD Cohort and Therapeutic Response to Brolucizumab. (PubMed, J Clin Med) - " PCV is remarkably underdiagnosed and overrepresented in the group of eyes with recalcitrant nAMD. Despite the inherent risk of IOI in response to bro, these results support the potential of bro as a third-line option for patients with eyes requiring anti-VEGF treatment every 6 weeks or less, provided that patients are monitored closely."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-world landscape of drug-related ocular injuries: a retrospective pharmacovigilance study. (PubMed, Front Pharmacol) - "The top three drugs by signal strength were brolucizumab (ROR = 132.15), macrogol 400 (ROR = 117.96), and cenegermin (ROR = 60.19)...TTO analysis indicated that most drugs exhibited an "early failure type" (β < 1), such as dupilumab (β = 0.68); only two drugs exhibited a random failure type. The risk of drug-related ocular injuries is primarily associated with sensory organ drugs and biologics, with the greatest risk occurring during the early treatment phase. Clinical monitoring should prioritize female and elderly patients, especially regarding ocular symptoms at the onset of drug therapy, to strengthen pharmacovigilance and inform personalized medication."

Adverse events • Journal • Real-world evidence • Retrospective data • Cataract • Oncology • Ophthalmology

Comparative effectiveness and safety landscape of anti-VEGF therapies for neovascular age-related macular degeneration: Insights from a systematic review and network meta-analysis. (PubMed, Biomed Pharmacother) - "All anti-VEGF agents stabilize or improve vision in nAMD. Aflibercept may provide the most favorable efficacy-safety balance, Faricimab offers promising durability, and Brolucizumab demonstrates large visual gains with potential safety concerns. Further head-to-head and long-term real-world studies are needed to optimize individualized treatment strategies."

HEOR • Journal • Retrospective data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-world efficacy and safety of Brolucizumab injection in vitrectomised eyes (BIVE) - a prospective multicentric study. (PubMed, BMC Ophthalmol) - No abstract available

Journal • Real-world evidence

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy. (PubMed, Int J Ophthalmol) - "Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC."

Journal • Retinal Disorders

Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series. (PubMed, Clin Exp Ophthalmol) - "Non-infectious hypertensive uveitis can occur subacutely after intravitreal faricimab injections. It is imperative that intraocular pressure is promptly managed to reduce the risk of permanent glaucomatous damage. As all our patients presented with anterior vitreous involvement, it is also practical that such cases of IOI are not mistaken for infectious exogenous endophthalmitis to avoid unnecessary treatment with intravitreal antibiotics and surgery."

Journal • Glaucoma • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis

Two-in-one protein tag enables the soluble expression and calcium-dependent purification of single-chain antibody fragments. (PubMed, Commun Biol) - "Importantly, the anti-VEGF-scFv produced with the CSQ-tag showed a binding affinity of 25.8 pM, similar to that of the existing therapeutic brolucizumab. Therefore, CSQ-tag can significantly improve productivity and simultaneously maintain scFvs' functional integrity, thereby serving as a promising tool for universal expression and purification of therapeutic scFvs."

Journal

Regional association between PM2.5 exposure and anti-VEGF treatment demand for age-related macular degeneration: a nationwide ecological study in Japan. (PubMed, Environ Sci Pollut Res Int) - "This nationwide analysis revealed a significant association between regional PM2.5 levels and the use of anti-VEGF intravitreal injections for macular diseases. No such relationship was observed for SOX, NOX, or PMD. These findings suggest that PM2.5 may contribute to the regional demand for AMD treatment, highlighting the need for further investigation into the impact of air pollution on ocular health."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype. (PubMed, Sci Rep) - "Although the number of additional injections was comparable between the two groups in the first 12 months (1.2 ± 1.4 vs. 1.7 ± 1.6, p = 0.29), the number of additional injections was significantly lower in the pachychoroid phenotype than in the non-pachychoroid phenotype (1.5 ± 2.4 vs. 3.2 ± 2.6, p = 0.0098) in the second 12 months. In the 24-month as-needed brolucizumab treatment group, the response to the pachychoroid phenotype was favorable, with significant BCVA improvement and fewer additional injections, particularly in the second 12 months."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-world database evaluation of drug-associated vitreous opacities and machine learning for clinical interpretability. (PubMed, Front Cell Dev Biol) - "The five highest-risk drugs were dexamethasone, brolucizumab, triamcinolone, faricimab, and fingolimod. This first systematic real-world evaluation of VO-related adverse drug reactions identifies high-risk drugs, susceptible populations, and onset patterns, thus offering guidance for preventive medication strategies. The BAG model showed higher sensitivity in real-world analysis, suggesting potential for further research in VO and floater prevention and treatment."

Journal • Real-world evidence

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. (PubMed, Invest Ophthalmol Vis Sci) - "The purpose of this study was to evaluate short-term intraocular blood flow changes post-intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in patients with neovascular age-related macular degeneration (nAMD), compare reductions across 4 agents (brolucizumab, faricimab, aflibercept 2 mg, and aflibercept 8 mg), and examine correlations between each agent's molar dose and the magnitude of 30-minute blood flow change. Aflibercept 8 mg produced a significant 30-minute reduction in ocular blood flow. Choroidal flow reduction was greater than with aflibercept 2 mg and negatively correlated with molar dose, suggesting a concentration-dependent hemodynamic effect."

Journal • Retrospective data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. (PubMed, PLoS One) - "Aflibercept 2 mg was the most common drug used overall from 2017-2023. Faricimab had the highest absolute and relative increase in utilization from 2022-2023. Patients with Medicare B or C were significantly more likely to receive aflibercept over bevacizumab."

Journal • Medicare • Reimbursement • Retrospective data • US reimbursement • Ophthalmology

VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "In poor-responsive nAMD, switching to BRZ or FAR under a TAE regimen without upload achieved stable vision, sustained CST reduction, and comparable treatment burden over one year. FAR showed greater fvPED regression and a slight functional trend, while BRZ achieved faster fluid resolution with fewer injections."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Quantitative optical coherence tomography angiography biomarkers Following a Switch to Brolucizumab in Neovascular age-related macular degeneration. (PubMed, Korean J Ophthalmol) - "Intravitreal brolucizumab demonstrated favorable anatomical improvements and maintained visual outcomes over 12 months. Quantitative OCTA biomarkers, particularly FD, may serve as imaging indicators of disease activity and treatment response in eyes with nAMD undergoing a therapy switch."

Biomarker • Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen. (PubMed, Sci Rep) - No abstract available

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Short-Term Outcomes of Intravitreal Brolucizumab Injection and Sub-Tenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema: A Pilot Study. (PubMed, J Vitreoretin Dis) - " Combination therapy with intravitreal brolucizumab and sub-Tenon triamcinolone acetonide may offer anatomic benefits in patients with DME, requiring fewer injections. Further evaluation using larger, prospectively designed studies is warranted to confirm its functional efficacy and long-term safety."

Journal • Diabetic Macular Edema • Inflammation • Ophthalmology

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy. (PubMed, Pharmaceuticals (Basel)) - "Complete regression of polypoidal lesions was observed in 62.5% and 75.0% of patients in the aflibercept and brolucizumab groups, respectively (p = 0.57). During the induction phase, aflibercept 8 mg demonstrated comparable outcomes to brolucizumab 6 mg in reducing CRT and SCT, achieving a dry macula, improving BCVA, and regressing polypoidal lesions in eyes with PCV."

Journal • Age-related Macular Degeneration

Laser Speckle Flowgraphy (LSFG) in Age-Related Macular Degeneration and Diabetic Retinopathy: A Systematic Review of Recent Literature. (PubMed, J Clin Med) - "Anti-VEGF injections produced acute reductions in MBR, particularly with brolucizumab, with partial recovery over time; drug-specific differences suggest a potential impact on geographic atrophy progression... LSFG provides reproducible, rapid, and non-invasive quantitative insights into ocular hemodynamics across degenerative retinal diseases. Its integration into multimodal imaging may facilitate early diagnosis, support personalized management, and assist in the prognostic assessment of retinal and choroidal vascular disorders."

Journal • Review • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Diabetic Retinopathy • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. (clinicaltrials.gov) - P4 | N=63 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Active, not recruiting | Phase classification: P ➔ P4

Enrollment closed • Phase classification • Diabetic Macular Edema • Ophthalmology